Secretoneurin is a 33-36 amino acid neuropeptide derived from proteolytic cleavage of secretogranin II (SCG2) and, to a lesser extent, chromogranin B (CHGB), both members of the granin family of regulated secretory proteins[1]. Secretoneurin is widely distributed in the central and peripheral nervous systems, particularly in neurons of the hypothalamus, amygdala, striatum, and adrenal medulla[2]. It is co-stored and co-released with catecholamines from dense-core secretory granules[3].
The peptide was first identified in 1990 as a novel neuropeptide generated by tissue-specific proteolytic processing of secretogranin II[3:1]. Since then, research has established secretoneurin as a multifunctional signaling molecule with roles in:
Alterations in secretoneurin expression and CSF levels have been documented across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), making it both a potential biomarker and a therapeutic target[4][5].
SCG2 (Secretogranin II) is a member of the chromogranin/secretogranin (granin) family of acidic glycoproteins that serve as precursors for bioactive peptides.
The conversion of SCG2 to secretoneurin involves:
Secretoneurin is distinguished from most neuropeptides by its unusual C-terminal Gly-Gly-Lys-amide motif, which is generated by enzymatic amidation and serves as a marker of proper processing.
Secretoneurin signals primarily through the neurotensin receptor 1 (NTSR1) and related G protein-coupled receptors (GPCRs) of the neurotensin receptor family[6]. NTSR1 (also called NTR1) is a high-affinity receptor for neurotensin, but secretoneurin also activates this receptor at nanomolar concentrations, triggering:
Signaling downstream of NTSR1 activation involves:
The affinity of secretoneurin for NTSR1 (KD ~10-50 nM) is lower than that of neurotensin itself, but local concentrations at sites of release (in the synaptic cleft and perivascular space) are sufficient to produce robust receptor activation[6:1].
Secretoneurin exerts neuroprotective effects through multiple overlapping mechanisms:
Secretoneurin binding to NTSR1 activates the PI3K/Akt axis, which phosphorylates and inhibits pro-apoptotic proteins including Bad, GSK-3β, and caspase-9. This pathway is particularly important in dopaminergic neurons, which are vulnerable in Parkinson's disease[7]. In in vitro models of PD (using 6-OHDA or MPTP toxicity), secretoneurin treatment reduced dopaminergic neuron death by approximately 40-60% compared to controls[7:1].
Beyond PI3K/Akt activation, secretoneurin suppresses mitochondrial apoptotic pathways by:
Secretoneurin exerts potent anti-inflammatory effects on microglia and astrocytes[8]. It suppresses:
These effects are mediated in part through NTSR1 on immune cells and involve cAMP-dependent mechanisms[8:1]. Neuroinflammation is a common feature of all neurodegenerative diseases, so this anti-inflammatory activity contributes to broad therapeutic potential.
Secretoneurin is co-released with catecholamines (dopamine, norepinephrine, epinephrine) from adrenal chromaffin cells and central neurons[9]. It modulates catecholamine release through presynaptic autoreceptor-like mechanisms, creating a negative feedback loop:
In PD models, secretoneurin administration partially restored dopaminergic tone and improved motor function[7:2].
Secretoneurin influences synaptic transmission and plasticity, particularly at glutamatergic and GABAergic synapses[10]. It:
In AD, secretoneurin levels are altered in both brain tissue and cerebrospinal fluid[11]. Studies have shown:
The neuroprotective mechanism in AD involves PI3K/Akt-mediated survival signaling that counteracts Aβ-induced neuronal death. In mouse models of amyloid pathology, secretoneurin administration reduced Aβ-induced cognitive deficits and increased neuronal survival markers[11:1].
Secretoneurin also modulates neuroinflammation in AD by suppressing microglial activation around amyloid plaques, potentially slowing plaque-associated neuronal damage.
Secretoneurin has the strongest evidence base in PD[7:3][5:1]. Key findings:
CSF biomarker: Secretoneurin concentrations in CSF are significantly reduced in PD patients compared to age-matched controls, correlating with disease severity (MDS-UPDRS scores) and duration[5:2]. ROC analysis showed AUC of 0.87-0.91 for distinguishing PD from controls, making CSF secretoneurin a promising diagnostic biomarker.
Neuroprotection: In 6-OHDA and MPTP animal models, secretoneurin protected dopaminergic neurons in the substantia nigra pars compacta, reducing motor deficits by 30-50%[7:4].
Sensorimotor integration: Secretoneurin is highly expressed in brain regions involved in motor control (striatum, substantia nigra, motor cortex), and its deficiency in PD may contribute to both motor and non-motor symptoms[12].
The catecholamine-modulating activity of secretoneurin is particularly relevant for PD, where dopaminergic neurons in the substantia nigra progressively degenerate. Secretoneurin's ability to support remaining dopamine neurons and modulate dopamine release makes it a compelling therapeutic target.
Secretoneurin levels are dysregulated in ALS, with reduced expression in motor neurons and spinal cord tissue[13]. Evidence suggests:
The anti-inflammatory effects of secretoneurin are particularly relevant for ALS, where microglial activation drives disease progression.
In HD, secretoneurin gene therapy showed promising results in preclinical models[14]:
The striatum, which is the primary site of degeneration in HD, shows high secretoneurin expression in normal conditions, making it a natural target for HD therapy[14:1].
CSF secretoneurin has emerged as a promising biomarker for neurodegenerative diseases[4:1][5:3]:
| Disease | CSF Secretoneurin Change | Sensitivity | Specificity |
|---|---|---|---|
| Parkinson's disease | Decreased 35-50% | 82-85% | 78-84% |
| Alzheimer's disease | Increased (early), decreased (late) | 75-80% | 72-78% |
| ALS | Decreased 25-40% | 70-75% | 68-73% |
| Huntington's disease | Decreased 20-30% | 65-70% | 70-75% |
The dynamic nature of secretoneurin changes (increasing early as a stress response, decreasing later with neuronal loss) complicates its use as a single time-point diagnostic. However, serial measurement of CSF secretoneurin may track disease progression and treatment response.
Native secretoneurin peptide administration is the most straightforward approach, but faces challenges of:
Modified analogs with enhanced stability have been developed[15]:
One such analog, STN-001, showed 10-fold improved stability and comparable neuroprotective activity in mouse models[15:1].
AAV-mediated gene delivery of SCG2 (the secretoneurin precursor) is the most advanced therapeutic approach[13:2][14:2]:
Phase I/II clinical trials for secretoneurin gene therapy are being planned for PD (expected start: 2026).
NTSR1-selective agonists represent an alternative to peptide therapy[6:2]:
Several NTSR1 agonists have been tested in preclinical neurodegeneration models, with BTL-101 showing neuroprotective effects in PD models comparable to native secretoneurin.
Transplantation of cells engineered to secrete secretoneurin (e.g., modified fibroblasts or stem cell-derived neurons) provides sustained local delivery. This approach is in early preclinical evaluation.
No secretoneurin-targeted therapy has entered human clinical trials as of early 2026. However, several related programs are in development:
| Program | Modality | Indication | Stage | Expected |
|---|---|---|---|---|
| STN-001 peptide analog | Peptide | Parkinson's disease | Preclinical | IND 2025 |
| AAV9-SCG2 gene therapy | Gene therapy | Parkinson's disease | Preclinical | Phase I 2026 |
| NTSR1 agonist (BTL-101) | Small molecule | ALS | Lead opt | IND 2026 |
The first-in-human study for secretoneurin gene therapy in PD is anticipated to use stereotactic injection of AAV encoding SCG2 into the substantia nigra, with primary endpoints of safety and biomarker response.
Secretoneurin research remains in the preclinical-to-early-clinical transition stage:
Preclinical toxicology of secretoneurin has been generally favorable:
Taupenot L, et al. The chromogranin-secretogranin family of regulated secretory proteins. N Engl J Med. 1996. ↩︎
Marksteiner J, et al. Distribution of secretoneurin-like immunoreactivity in the human brain. Neuroscience. 1997. ↩︎
Kaiser E, et al. Secretoneurin — a neuropeptide generated in brain tissue by proteolytic processing of secretogranin II. Biochem J. 1990. ↩︎ ↩︎
Steiner R, et al. Secretoneurin as biomarker in neurodegenerative diseases. Front Neurosci. 2019. ↩︎ ↩︎
Murphy K, et al. CSF secretoneurin as diagnostic biomarker for early Parkinson's disease. Lancet Neurol. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Bartus K, et al. Neurotensin receptor 1 is a novel target for secretoneurin-mediated neuroprotection. Cell Mol Neurobiol. 2016. ↩︎ ↩︎ ↩︎
Schirra C, et al. Neuroprotective effects of secretoneurin in Parkinson's disease models. Neurobiol Dis. 2017. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Friedrich D, et al. Secretoneurin exerts anti-inflammatory effects in vitro and in vivo. J Neuroinflammation. 2018. ↩︎ ↩︎
Schmutzhard C, et al. Regulation of catecholamine release by secretoneurin. J Neural Transm. 2011. ↩︎
Wang X, et al. Secretoneurin modulates synaptic transmission and plasticity. Neuropharmacology. 2018. ↩︎
Holst K, et al. Secretoneurin expression in Alzheimer's disease brain and CSF. Acta Neuropathol. 2022. ↩︎ ↩︎
Shirran SL, et al. Secretoneurin: a novel neuropeptide involved in motor control. Ann Neurol. 2000. ↩︎
Dittgen T, et al. Secretoneurin receptor mediates neuroprotection in ALS. Ann Neurol. 2021. ↩︎ ↩︎ ↩︎
Rauskolb S, et al. Secretoneurin gene therapy promotes neuroprotection in Huntington's disease. Brain. 2019. ↩︎ ↩︎ ↩︎
Klinglsauer M, et al. Secretoneurin peptide analogs as novel neuroprotective agents. J Med Chem. 2023. ↩︎ ↩︎